FitLife Brands, Inc. (FTLF)
NASDAQ: FTLF · Real-Time Price · USD
7.98
-0.02 (-0.27%)
At close: Nov 6, 2026, 4:00 PM EST
7.97
-0.01 (-0.10%)
After-hours: Nov 6, 2026, 7:30 PM EST

FitLife Brands Earnings Call Transcripts

Fiscal Year 2026

  • The portfolio has grown through online expansion and acquisitions to over $100 million in LTM revenue, while addressing margin pressures and organic growth headwinds. Management sees renewed positive organic growth as key to sustaining cash-funded consolidation and valuation recovery.

  • Q2 2026 revenue surged 65% year-over-year to $26.5 million, driven by the Irwin acquisition, while gross margin declined due to Irwin's lower margin profile. Legacy FitLife saw revenue and margin declines, but sequential improvements and debt reduction signal positive momentum.

  • Q1 2026 revenue rose 59% year-over-year to $25.3M, driven by the Irwin acquisition, but net income fell to $1.7M due to higher amortization and interest. Gross margin declined to 37.6%, while Irwin's Amazon business and new MusclePharm SKUs in Kroger stores signal growth opportunities.

Fiscal Year 2025

  • Fourth quarter revenue surged 73% year-over-year, driven by the Irwin acquisition, but gross margin declined due to Irwin's lower historical margins. Ongoing macro and Amazon-related headwinds are pressuring most brands, though Irwin's online growth and debt reduction efforts are bright spots.

  • Q3 revenue rose 47% year-over-year to $23.5M, driven by the Irwin Naturals acquisition and strong MusclePharm growth, but margins declined due to higher protein costs and integration expenses. Consumer softness and Amazon algorithm changes present ongoing risks.

  • Q2 2025 saw a 5% revenue decline and lower net income due to M&A costs, but the Irwin Naturals acquisition positions the business for over $120 million in annual revenue and $20–$25 million adjusted EBITDA. Gross margins are expected to improve as online sales grow.

  • Revenue declined 4% year-over-year to $15.9M, with net income at $2M and adjusted EBITDA down 6%. Legacy FitLife grew, while MRC and MusclePharm saw declines. Gross margins are expected to remain stable, and M&A activity continues to be a strategic focus.

  • The company has transformed from a distressed, wholesale-focused business to a profitable, online-driven operator with a diversified brand portfolio. Strategic acquisitions and disciplined M&A have fueled growth, while management's alignment with shareholders and operational efficiency underpin strong financial performance.

Fiscal Year 2024